IE902252L - Novel acetylcholinesterase inhibitors - Google Patents

Novel acetylcholinesterase inhibitors

Info

Publication number
IE902252L
IE902252L IE902252A IE225290A IE902252L IE 902252 L IE902252 L IE 902252L IE 902252 A IE902252 A IE 902252A IE 225290 A IE225290 A IE 225290A IE 902252 L IE902252 L IE 902252L
Authority
IE
Ireland
Prior art keywords
alkyl
compound
compounds
formula
cf2x
Prior art date
Application number
IE902252A
Other versions
IE66155B1 (en
IE902252A1 (en
Inventor
Daniel Schirlin
Jeannoel Collard
Jeanmarie Hornsperger
Original Assignee
Desmond Joseph Crosdale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Desmond Joseph Crosdale filed Critical Desmond Joseph Crosdale
Publication of IE902252L publication Critical patent/IE902252L/en
Publication of IE902252A1 publication Critical patent/IE902252A1/en
Publication of IE66155B1 publication Critical patent/IE66155B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)

Abstract

This invention relates to silylated aromatic fluoroketones of the formula (I) <CHEM> and the pharmaceutically acceptable salts thereof, wherein each of m and n is zero or one with the proviso that the sum of m and n is less than two. X is H, Br, Cl, F, R4, COR5, CO2R5, CONHR5 or COR6; R1, R2, R3 and R4 each are C1-10 alkyl, or (CH2)p aryl, with p being zero, one or two, R5 is H, C1-10 alkyl, phenyl, benzyl or phenethyl, R6 is (NHCHR7C(O))qR8 with R7 being the residue of any natural occurring alpha -amino acid, q is one to four and R8 is OR5 or NHR5, Y is H, OH, C1-6 alkyl, C1-6 alkoxy, hydroxy C1-6 alkyl, amino C1-6 alkyl, NH2, azido, CN, CO2R5, COR5, -SO3H, Br, Cl, F or -(CH2)xSiR1R2R3with x being zero, one or two, possessing acetylcholinesterase properties and to their use in the treatment of Alzheimer's disease and senile dementia. [EP0403713A1]

Description

IE 902252 NOVEL ACETYLCHOLINESTERASE INHIBITORS 10 15 20 This invention relates to silylated aromatic fluoro-ketones, to the intermediates and processes for their preparation and to their use in treating diseases associated with deficiencies of cholinergic transmission in the central nervous system.
More specifically, this invention relates to silylated aromatic fluoroketones possessing acetylcholinesterase-inhibiting properties and to their use in the treatment of Alzheimer disease and senile dementia.
Still more specifically, this invention relates to acetylcholinesterase inhibitors of the formula 25 30 m01414a b - l - IE 902252 H (CH2)n-Q-CF2X Y 5 H R3-SiR 10 and the pharmaceutically acceptable salts thereof, wherein each of m and n is zero or one with the proviso that the sum of m and n is less than two, R,, R2, R3 and R4 each are C110 alkyl, or (CH2)p aryl, with p being zero, one or two, 25 Rs is H, C110 alkyl, phenyl, benzyl or phenethyl, R9 is Cx 10 alkyl, phenyl, benzyl or phenethyl, Re is (NHCHR7C(0) )qRg with R7 being the residue of any natural 2Q occurring a-amino acid, q is one to four and R8 is 0R5 or NHRS, Y is H, OH, Cj^ alkyl, C^ alkoxy, hydroxy alkyl, amino C1-6 alkyl, NH2, azido, CN, CO^j, COR9, -S03H, Br, CI, F or -(CH2)xSiR1R2R3 with x being zero, one or two. 15 Q is -C-, -CH or -CH with R being H or CM0 alkyl 0 OH 0-C-R II 0 20 X is X1 or X" withX' being H, Br, CI, F or R4 and X" being COR9, C02R5, CONHR5 or CORfi, 35 M01414A - 2 - IE 902252 As used herein the term "alkyl" includes the straight, branched-chain and cyclized saturated hydrocarbyl moieties having up to 10 (or 6 as otherwise indicated) particularly including such moieties as methyl, ethyl, n-butyl, t-butyl, 5 cyclopropyl, n-propyl, pentyl, hexyl, n-nonyl, decyl, cyclo-pentyl, cyclohexyl and cyclohexylmethylene. The term "aryl" within the definitions for R,, R2, R3 and R4 includes both carbocyclic and heterocyclic moieties of which phenyl, pyridyl, indolyl, indazolyl, furyl and thienyl are of primary interest; these moieties being inclusive of their position isomers such as, for example, 2-, 3-, or 4-pyridyl, 2- or 3-furyl and thienyl, 1-, 2-, or 3-indolyl or the 1- and 3-indazolyl, as well as the dihydro and tetrahydro analogs of the furyl and 15 thienyl moieties. Also included within the term "aryl" are such fused carbocyclic moieties as pentalenyl, indenyl, naphthalen-yl, azulenyl, heptalenyl, acenaphthylenyl, fluorenyl, phenalen-yl, phenanthrenyl, anthracenyl, acephenanthrylenyl, aceanthryl-enyl, triphenylenyl, pyrenyl, chrysenyl and naphthacenyl. Also on included within the term "aryl" are such other heterocyclic radicals as 2- or 3-benzo[b] thienyl, 2- or 3-naphtho[ 2,3~b] thienyl, 2- or 3-thianthrenyl, 2H-pyran-3-(or 4- or 5-)yl, 1-isobenzo-furanyl, 2H-chromenyl-3-yl, 2- or 3-xanthenyl, 2- or 3-phenoxa-thiinyl, 2- or 3-pyrrolyl, 4- or 3-pyrazolyl, 2-pyrazinyl, 2-pyrimidinyl, 3-pyridazinyl, 2-pyrimidinyl, 3-pyridazinyl, 2-indolizinyl, 1-isoindolyl, 4H-quinolizin-2-yl, 3-isoquinolyl, 2-quinolyl, 1-phthalazinyl, 1,8-naphthyridinyl, 2-quinoxalinyl, 2-quinazolinyl, 3-cinnolinyl, 2-pteridinyl, 4aH-carbazol-2-yl, 30 2-carbazolyl, p-carbolin-3-yl, 3-phenanthridinyl, 2-acridinyl, 2-perimidinyl, 1-phenazinyl, 3-isothiazolyl, 2-phenothiazinyl, 3-isoxazolyl, 2-phenoxazinyl, 3-isochromanyl, 7-chromanyl, 2-pyrrolidinyl, 2-pyrrolin-3-yl, 2-imidazolidinyl, 2-imidazol-in-4-yl, 2-pyrazolidinyl, 3-pyrazolin-3-yl, 2-piperidyl, O c 2-piperazinyl, 1-indolinyl, 1-isoindolinyl, 3-morpholinyl, benzo[h]isoquinolinyl, and benzo[b]furanyl, including the M01414A - 3 - IE 902252 position isomers thereof except that the heterocyclic moieties cannot be attached directly through their nitrogen atoms.
The term [NHCHR7C(0) ] of Rfi represents an a-amino acid or g a peptide of up to 4 amino acids, with R7 being the residue of any of the naturally occurring a-amino acids (including proline in its natural form) including alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenyl-10 alanine, serine, threonine, tryptophan, tyrosine, valine, nor-valine, n-leucine, 1-naphthylalanine, 2-indolinecarboxylic acid and sarcosin. Of course when q is other than 1 the amino acid moieties may be the same or different. Preferably Rg represents either OH or NH2 but includes the R5 variants thereof, particularly when R5 is methyl or ethyl.
The pharmaceutically acceptable salts of the compounds of formula I include salts formed with non-toxic organic or inorganic acids such as, for example, from the following acids: 20 hydrochloric, hydrobromic, sulfonic, sulfuric, phosphoric, nitric, maleic, fumaric, benzoic, ascorbic, pamoic, succinic, methanesulfonic, acetic, propionic, tartaric, citric, lactic, malic, mandelic, cinnamic, palmitic, itaconicand benzenesulfonic. p C The preparation of the compounds of formula I may be effected by a variety of procedures, the choice depending upon the specific combination of the X, Y, m, n, R,, R2 and R3 moieties for any given compound. In any event, the chemical 2Q reactions and procedures are analogously known in the art and the selection of any particular route to prepare any particular compound is governed by principles well known and appreciated by those of ordinary skill in the art. Thus, by the application of the below-described procedures and chemical processes 35 generally well-known in the art, the compounds of this invention may be prepared.
M01414A - 4 - IE 902252 To prepare compounds of subgeneric formula 0 o •cf2x' SiRjRjjRg A-10 i.e., those compounds of formula I wherein m and n are zero, Y is H, and X' is H, CI, Br, F or Rj( the compounds may be prepared by the following reaction scheme. 15 Reaction Scheme A 20 (a) Br SiRjR2R3 (b) SiRjRgRg 25 30 35 A-11 A-12 A-13 wherein Rx, R2, R3 and R4 are as defined in formula I, and X1 is H, CI, Br, F or R4. In the initial step (A-a) the reaction involves the treatment of the dibromo compounds (A-11) with ClSiRjR2R3 in the presence of one equivalent of magnesium in a suitable solvent such as diethylether or tetrahydrofuran (THF), said reaction taking place at about the reflux temperature of the mixture to obtain the silylated derivatives (A-12) which, by Step (A-b), are converted to their intermediate lithio derivatives by reaction with an alkyllithium at 0°C in diethyl ether or THF and those intermediates are converted to the desired products (A-13) by reaction with three equivalents of the appropriate acid, (preferably as its lithium m01414a - 5 - IE 902252 salt) ester (X'CFgCOgR), or acid chloride (X'CF2COCl) with R being H or Cj^ alkyl, preferably methyl or ethyl). The ketones may be reduced with sodium borohydride or sodium cyano borohydride by reaction in ethanol followed by hydrolysis with 5 saturated ammonium chloride and the resulting alcohols esterified with an acyl halide (CIC(O)R with R being H or Cx10 alkyl), in the presence of TEA (or neat pyridine) in a suitable solvent such as dichloromethane; both these reactions being effected according to well known and understood reaction conditions.
In those instances wherein it is desired to prepare compounds of this invention which are within the sub-generic 1 (■ scope of the formula Y 20 SiRjRgRg B-10 25 wherein n = m = o, Y is other than H, and X1 is H, Br, CI, F or R4, the chemistry of the following reaction scheme may be utilized. 30 35 M01414A - 6 - IE 902252 Reaction Scheme B H h2N r O 10 15 20 25 30 35 SiRjR2^3 SiRjR2R3 B-15 B-14 H OAc H OAc h„n ~r O cf2x' -H SiRtR2R3 Y—O S iRjR2R3 cf2x" B-17 B-18 l' H 0 Y-f O S^H SiRjR2R3 "CFgX1 H OH jk Y-hO cf2x' B-20 VH S iRjR2R3 B-19 M01414A - 7 - IE 902252 10 Again, in effecting the foregoing reactions, standard procedures analogously known in the art are employed. Step (B~a) entails the treatment of the amines (B-ll) with one equivalent of butyl lithium in THF at about ~30°C to form an in situ intermediate which is reacted with one equivalent of 1,4-dichloro-l,1,4,4-tetramethyldisilylethylene at about -78°C. The stabase adduct intermediates (B-12) are subjected to Step (B-b) using the silylation process of Step (A-a) and the resulting products CB—13) by Step (B-c) are sequentially converted to their lithio derivatives by reaction with butyl lithium in diethylether at 0°C for 15 minutes and these lithio derivatives are reacted with 3 equivalents of an acid, ester (X'CF2C02R) or a lithio salt thereof, or acid chloride (X'CFgCOCl) at -78°C to obtain products (B-14). Alternatively using Step (B-d), which in principle follows Step (B-c), except that the hydrolysis is performed preferably using an aqueous ammonium chloride solution to produce compounds (A-15). Step (B-e) reduces the ketones of (B-15), preferably using sodium 20 cyanoborohydride in ethanol followed by hydrolysis with a saturated aqueous ammonium chloride solution to produce the alcohols of (B-16). Using Step (B-f) the alcohols are protected by reaction with an acyl halide, preferably acetyl chloride, in the presence of triethylamine (TEA) in a solvent such as dichloromethane followed by an acid hydrolysis, preferably using IN HC1 to convert the stabase adduct to an amine (in the form of an ammonium salt) to obtain products (B-17). Step (B-g) involves a multiplicity of reactions which essentially are designed to effect Y-substitution on the phenyl ring of the involved compounds of (B-17). In general, these reactions involve the conversion of the ammonium salt to a diazonium salt (e.g., as with a reaction sodium nitrite or pentinyl nitrite in ice water) followed by treatment of the mixture with a metal 35 salt or other derivative of Y to obtain the variety of Y-substituted derivatives. The Y-substituents involved are 25 30 M01414A - 8 - IE 902252 those as defined in formula I and include such moieties as OH, alkyl, alkoxy, hydroxy lower alkyl, amino alkyl, azido, cyano, car boxy 1, C02R5, C0R5, S03H, Br, CI, F or (CH2)xSiR1R2R3. g More specifically, Step (B-g) involves substitution of the (B-17) compounds with the foregoing enumerated Y-substituents. Preferably, the amine of B-17 is converted to N2®HS04e or N2®Cle diazonium salts and by a variety of reactions the Y-substituted compounds of (B-18) are prepared. To prepare compounds wherein 10 Y is OH, a so-prepared diazonium salt is dissolved in water, heated at about 80 to 120°C to produce the desired hydroxy function which may be converted to its alkoxy derivative by alkylation in the presence of a base and the appropriate alkyl halide. To produce a fluoro derivative the diazonium salt (formed with BF4eN2®) is heated at 140° to 160°C to obtain the desired fluoro derivatives.
For the chloro and bromo the diazonium sulfate or chloride salt is treated with cuprous bromide or chloride to obtain the 20 desired bromo or chloro derivatives. To obtain the azide the diazonium salt is treated with sodium azide in water. The cyano derivative is obtained by treatment of the diazonium salt with cuprous cyanide. The carboxy moiety may be obtained by 2g hydrolysis (in a basic aqueous medium) of the cyano moiety and, if desired, the acid may be esterified with the appropriate R5 alcohol, in the presence of DCC and DMAP, to obtain the appropriate -C02R5 moiety. The -S03H moiety may be obtained by treating the diazonium salt with cupric chloride in the 30 presence of HC1 to obtain the S02C1 moiety which, when treated with water, gives the desired -S03H moiety. To obtain the desired ~C0R5 moiety the diazonium salt is treated with an oxime [R5CH=N0H] in the presence of copper sulfate and sodium sulfite, the resulting oxime is hydrolized to obtain the desired acyl moiety (Y is [0=C-R5]), the ketone of which is M01414A - 9 - IE 902252 reduced with sodium borohydride and the resulting alcohol (HOCRj) is subjected to a Mitsunobu reaction to form a phthalamide which, upon treatment with hydrazine, is cleared to obtain the H„N-C-R- amine. In those instances wherein Y is 5 2,5 a -SiRjRjRg substituent the starting compound is a tribromo-benzene which is treated as in Step (A-a) except that two equivalents of magnesium and ClSiRjR^g are used to obtain the derivative corresponding to (B-16) which by Step (A-b) is 10 converted to (B-20) wherein Y is a -SiRxR2R3 moiety.
Following the formation of the Y-substituted compounds of formula (B-18), step (B-h) is employed to remove the alcohol-protecting group by hydrolysis (e.g., Ac) under basic or acidic 15 conditions (taking in consideration of the now-present Y-substituents) according to principles and techniques well-known and understood by those of ordinary skill in the art. The resulting alcohols (B-19) are subjected to Step (B-i) wherein the alcohol is oxidized with pyridinium dichromate or with the ^ Dess-Martin periodane oxidant in dichloromethane or with the Swern reaction to produce compounds (B-20). Alternatively, the alcohols may be esterified, as described above, with an acyl halide.
^ In those instances wherein it is desired to prepare compounds of formula I represented by the sub-generic formula 30 35 M01414A - 10 - IE 902252 20 SiRjI^Rg 10 C-10 15 i.e., those compounds wherein n and m are zero, Y is H, and X* is C0R9, C02R5, C0NHR5 or C0Rg, it is preferred to utilize the process of the following reaction scheme. 25 30 35 M01414A - 11 - IE 902252 10 15 20 25 30 35 Reaction Scheme C oh O O "oh o -h Br C-11 SiR.jR.2R3 C-12 SiRjRjRg C-13 i' OH oh o cf2cor9 b O ■cf2cor9 d O -CF2C02Et sirjr2r3 C-16 SiRjRjRg C-15 o SiRjRjRg C-14 oh -cf2co2h SiRjRgRg C-17 oh o -cf2co2r5 SiRjR2R3 C-18 i' cf2cor6 0 0 o ■cf2co2r5 o •cf2conhr5 o ■cf2c0r6 SiRjR2Rg C-19 SiRjR^g C-21 SiRjRgRg C-23 M01414A - 12 - IE 902252 15 Step (C-a) involves the treatment of 3-bromobenzylalcohol (C-11) with 2 equivalents of butyl lithium in diethyl ether at g 0°C, treat the resulting lithio derivatives with 2 equivalents of the desired ClSiRjR2R3 and stir the resulting mixture at room temperature until the reaction is complete (generally 15-24 hours). Hydrolize, and after extraction, treat the crude product in 90% aqueous methanol for one hour at reflux 10 temperature to obtain the silylated alcohols (C-12). Step (C-b) oxidizes the alcohols with pyridinium dichromate in dichloromethane to obtain the aldehydes (C-13) which, in Step (C-c), are treated with an alkyl bromo difluoroacetate in THF in the presence of zinc at reflux temperatures to obtain intermediary hydroxy difluoroesters (C-14). In Step (C-d) these esters (C-14) are treated with two equivalents of a metallo derivative, preferably a lithium or magnesium derivative of the R9 moiety, in diethyl ether or THF to obtain compounds (C-15) which, as in Step (C-b) are oxidized to their corresponding ketones (C-16) using pyridinium dichromate or the Swern or Dess-Martin reactions. Alternatively, using Step (C-e) the hydroxy difluoro esters of formula (C-14) may be hydrolized by treatment with lithium hydroxide in 80% aqueous ethylene glycol dimethylether 25 to obtain the corresponding hydroxy difluoro acids (C—17).
These acids, using Step (C-f) may be treated with an alcohol (R50H) in the presence of dicyclohexyl carbodiimide and 4-dimethylamino pyridine to obtain the esters (C-18). Alternatively, using Step (C-g) the acids (C-17) may be treated with an amine (R5NH2) in the presence of dicyclohexylcarbodi-imide and 1-hydroxybenzotriazole to obtain the amides of formula (C-20). Using Step (C-h) the hydroxy difluoro acids (C-17) may also be reacted with a natural occurring amino acid, 25 or a peptide R6H in the dicyclohexylcarbodiimide and 1-hydroxy-benzotriazole to obtain the products of formula (C-22). In each 20 30 M01414A - 13 - /e 902252 instance, using the oxidation step of (C-b), the alcohols of (C-15), (C-18), (C-20) and (C-22) may be oxidized to the corresponding ketones of formulae (C-16), (C-19), (C—21) and (C-23), respectively, or they may be esterified, as described 5 above, with an acyl halide.
In those instances wherein it is desired to prepare compounds of the subgeneric formula 10 Y'- 15 h 0 o sirjrgrg cf2x" D-10 20 i.e., those compounds wherein n and m are zero, Y' is other than h, X" is C0R9, COgRj, CONHRj or C0Re, the following reaction scheme is utilized. 30 35 M01414A - 14 - 902252 Reaction Scheme D h 'Br h„n r O Br D-11 h oh G O CF„C02Et . 22 hn -h o SH SiRjRgRg D-16 f ) i h oh hn O Boc y^H SiRjRgRg D-17 g w h oh hn O BocV^H sirjr2r3 •cf2cor9 D-18 d i ( h 0 hn-4-O BocSr^H SiRjR2R3 iiocV^H SiRjR^ SiRjRjRg D-15 h oh D-14 h oh •CF2C02Et hn O BocSf^® SiR}R2R3 -cf2co2h hn O BocS^H SiR,R2R3 cf2cor6 D-21 |j — h oh h oh hn —o Boc'V^11 ■cf2co2r5 sirjr2r3 D-22 i' hn-hO Boc SiRxR2R3 D-25 cf2c0nhr5 i' h 0 h 0 •CF2C0R9 hn I o BocN^H SiRjR2R3 •cf2co2r5 hn O kocV^H SiRjR2R3 -cf2conhr5 D-19' D-23" D-26* M01414A - 15 - IE 902252 Reaction Scheme P (cont'd) H 0 h 0 hn — o BocS^-H SiR.SjB, cf2cor6 H„N d-16 d-29 CF2C02Et n _ o V^H SiRjRjRg d-30 ^cf2cor6 SiRjR2R3 d-31 h oh CF'C°'Et Y1—L O •cf2cor9 SiRjR2R3 d-33 h 0 cf2co2h y'-I-o -2+ -cf2cor9 SiRjR2R3 d-35 SiR^^ d-34 h oh h oh yL-^o •cf2c02r5 y| q | cf2conhr5 CFjcor, t SiR,R2R3 p-36 d h 0 SiRjRjRj d-38 d t Y —- O SiR^Ra h 0 I ^cf2CO2R5 Y!_|_o I "^CF-CONHR SiR^ d-40 ld 0 f h 0 . AA- v^H d-37 SiRjR2R3 d-39 2*****•*•»•* siRiRA D-41 -cf2cor6 M01414A - 16 - IE 902252 [*Compounds (D-19), (D-23), and (D-26) are de-Boced to desired compounds (D-20), (D-24), and (D-27) according to step D-h.] Compound (D-13) is obtained according to Steps (D-a) and g (D-b) using proceses (B-a) and (B-b).
The stabase adducts (D-13), using Step (D-c) are reacted with one equivalent of magnesium in diethylether and the resulting in situ intermediate treated with paraformaldehyde (followed by hydrolysis with saturated aqueous ammonium chloride solution) to form the appropriate hydroxymethyl compounds (D-14) which, using Step (D-d), are oxidized according to Step (C-b) and the resulting aldehydes (D-15) using Step (D-e) are converted to their esters (D-16) according 15 to (C-c). Using Step (D-f) these esters are treated with IN HC1 to convert the stabase adduct to its amine and the amine is protected with a Boc protecting group to produce compounds (D-17). These intermediates [using Steps (D-g), (D-d) and (D-h)] are sequentially converted to compounds (D-18), (D-19) ? o and (D-20) using the processes described for Step (C-d) (using 3 equivalents of the metallo derivatives of R5), Step (C-b) and Step (D-h) which is treatment of the Boc derivatives with a solution of HC1 in diethyl ether. Compounds (D-17) may also be 20 sequentially converted to (D-21) by Step (D-i) [as described in Step C-e)], then by Step (D-f) to (D-22), then by Step (D-d) [as described in (C-b)] to (D-23), then by Step (D-h) to (D-24). 2Q Compounds (D-21) also may be sequentially treated according to Step (D-k) (see C-g) to obtain (D-25) which are converted to (D-26) according to Step (D-d) (see C-b) and to (D-27) according to Step (D-h). Compounds (D-21) also may be sequentially treated according to Step (D-l) (see C-h) to 35 produce (D-28) to (D-29) according to Step (D-d) (see C-b) and then to compounds (D-30) by Step (D-h).
M01414A - 17 - IE 902252 From compound (D-16), compounds (D-34), (D-37), (D-39) and (D-41) may be obtained using the above described chemistry. The alcohols of (D-33), (D-36), (D-38), and (D-40) may be oxidized to their ketones or they may be converted to their esters as hereinabove described. 10 To prepare compounds of formula -CH O 2y 0 cf2x' SiRjRjRa 15 20 E-10 i.e., compounds wherein n is one, m is zero, Y is H, and X1 is H, Br, CI, F or R4, the following reaction scheme is utilized Reaction Scheme E 25 30 O xh2oh (a) SiRjRjjRg E-11 CH20Et (b) SiRjRjRg E-12 SiRjRgRg E-13 In this sequence, silylated compounds (E-11) are treated with n-butyllithium and then with ethyl iodide to produce 35 compounds (E-12) which, by treatment with six equivalents of lithium in diethyl ether or THF at -10°C, produce an in situ M01414A - 18 - IE 902252 intermediate to which is added an acid, ester (X'CFgCO^ wherein R is H or C^ alkyl) or an acid chloride (X'CF^OCl), followed by hydrolysis with IN HC1 to obtain compounds (E-13). These ketones may be reduced with sodium borohydride or sodium 5 cyano borohydride by reaction in ethanol followed by hydrolysis with saturated ammonium chloride and the resulting alcohols esterified with an acyl halide (CIC(O)R with R being H or Cx10 alkyl), in the presence of TEA (or neat pyridine) in a suitable solvent such as dichloromethane; both these reactions being effected according to well known and understood reaction conditions.
To prepare compounds of formula 15 SiRjRgRg MO 25 i.e., compounds wherein n is one, m is zero, Y' is other than H, and 30 X' is H, Br, CI, F or R4, the following reaction scheme is utilized. 35 M01414A - 19 - 902252 Reaction Scheme F 10 -Br h2n O r Br F-11 G o Br -Br F-12 G+° -Br SiRjR2R3 F-13 15 20 25 30 35 SiRjRjRg F-17 cf„x* SiRjRjRg F-18 SiRjR2R3 F-16 SiRjR2Rg F-14 SiRjRgRg F-15 Yif o y-M-O cf2x* SiR,R2R3 F-19 F-20 SiRjRgRa F-21 M01414A - 20 - IE 902252 10 Step (F-a) forms the stabase adduct (F-12) with process (B-a).
Step (F-b) silylates (F-12) to (F-13) with process (A-a).
Step (F-c) treats ((F-13) with butyllithium at 0°C in ether or THF and then treats with dibromomethane to obtain (F-14).
Step (F-d) treats (F-14) with magnesium in diethyl ether or THF at reflux, then at -78°C intermediate is treated with ester (X'CF2C02R) or acid chloride (X'CF2C0C1), followed by hydrolysis with IN HC1 to obtain (F-15).
Step (F-e) treats (F-14) as in Step (F-d) except the hydrolysis is effected with an ammonium chloride solution to obtain (F-16).
Step (F-f) treats (F-16) according to process (B-e) to obtain 15 (F-17).
Step (F-g) treats (F-17) according to process (B-f) to obtain (F-18).
Step (F-h) treats (F-18) according to process (B-g) to obtain (F-19).
Step (F-i) treats (F-19) according to process (B-h) to obtain (F-20).
Step (F-j) treats (F-20) according to process (B-i) to obtain (F-21). The alcohols (F-20) may also be esterified with an acyl halide as hereinabove described. 20 25 30 To prepare compounds of formula 35 SiRjRjSj G-10 M01414A - 21 - IE 902252 i.e., compounds wherein n is one, m is zero, Y is H, and X" is C0R9, C02R5, C0NHRg or C0Rg, the following reaction scheme is utilized. 10 15 20 25 30 M01414A - 22 - IE 902252 Reaction Scheme G -ch, O o Br G-11 'ch„ SiRjR2R3 o -Br G-12 cf2cor8 SiRjR2R3 SiRjRjRg G-13 CF2C0Et oh SiRjR2R3 G-16 cf2cor9 cf2co2h SiRjR2R3 G-18 s lrjr^ G-19 cf2co2r5 o -CHoOH SiRjR2R3 G-14 cf2co2r5 SiRjRgRg G-21 cf2cor6 cf2c0rfl M01414A - 23 - IE 902252 10 Step (G-a) silylates compounds (G-ll) to form compounds (G-12) according to process (A-a).
Step (G-b) treats compounds (G-12) to form compounds (G-13) by treatment with one equivalent of N-bromosuccinamide in CC14 at reflux temperatures.
Step (G-c) treats compounds (G-13) according to process (D-c) to obtain compounds (G-14).
Step (G-d) treats compounds (G-14), (G-17), (G-20), (G-22) and (G-24) according to process (C-b) to obtain compounds (G-15), (G-18), (G-21), (G—23) and (G-25).
Step (G-e) treats compounds (G-15) according to process (C-c) to obtain compounds (G-16).
Step (G-f) treats compounds (G-16) according to process (C-d) jg to obtain compounds (G-17).
Step (G-g) treats compounds (G-16) according to process (C-e) to obtain compounds (G-19).
Step (G-h) treats compounds (G-19) according to process (C-f) to obtain compounds (G-20). 20 Step (G-i) treats compounds (G-19) according to process (C-g) to obtain products (G-22).
Step (G-j) treats compounds (G-19) according to process (C-h) to obtain compounds (G-24). The alcohols of (G-17), (G-21), (G-23), and (G-25) may also be esterified with an acyl halide oc as hereinabove described. 30 35 M01414A - 24 - IE 902252 10 To prepare compounds of formula CF2X" sirjrgrg H-10 i.e., compounds wherein n is one, 15 m is zero, Y is other than H, and X1' is C0R9, C02R5, C0NHR5 or C0R6, the following reaction scheme is utilized. 20 25 30 35 M01414A - 25 - IE 902252 Reaction Scheme H 10 H o+° Br H-12 -Br G-h° -Br H-13 c \' 15 20 25 30 f2cor9 sirjrgrg H-17 I" H-32 SiRjRjK-s H-18 SiRjR2Rg H-19 h„n r o \e H " /-cf2cor5 r hn 4-0 F2C0R» Boc SiRjR2Rg SiRjR2R3 35 H-21 H-20 M01414A - 26 - IE 902252 Reaction Scheme H (cont'd) 10 H-18 cf2co2h SiRjR2R3 H-22 cf2co2r5 hn- SiRjR2R^ H-23 le 20 sirjrgrg H-24 30 Boc cf2conhr5 SiRjR2R3 H-26 SiRjR2Rg H-29 cfoc0or, CFoc0nhr SiRjRgRs H-27 SiRjRgRa H-30 h2n- cf2co2r5 h„n o cf2conhr5 h„n 35 SiRjRjjRg H-25 SiRjRjjR^ H-28 SiRjR2Rg H-31 M01414A - 27 - IE 902252 Reaction Scheme H (cont'd) h h CF2C02Et O V— o 10 15 SiRjRgRa H-32 CF2COR9 CF2C02Et h ^ Y! cf2cor9 SiRjRjRs H-33 SiRjRgR^ H-34 cf2co2h Y'—O cf2cor9 SiRjRjRg SiRjRgRg 20 25 H-36 H-35 cf2co2r5 YI-O cf2cor6 SiRjRjRg H-37 le 30 I' SiRjRgRg H-38 le SiRjRjRg \' cf2co2r5 Y-- O Y' O 35 SiRjR2Rg H-38 CF„CONHR cf2cor6 SiRjRjRg H-42 M01414A - 28 - IE 902252 Step (H-a) converts compounds (H-ll) to their stabase adducts according to the process of (B-a) to obtain compounds (H-12).
Step (H-b) converts compounds (H-12) to compounds (H-13) ^ according to process (B-a).
Step (H-c) converts compounds (H-13) according to process (F-c) to obtain products (H-14).
Step (H-d) converts compounds (H-14) according to process (D-c) to obtain products (H-15).
Step (H-e) converts compounds (H-15), (H—19), (H-23), (H-26) and (H-29) according to process (C-b) to obtain products (H-16), (H-20), (H-24), (H-27) and (H-30), respectively.
Step (H-f) converts compounds (H-16) according to process (C-c) 15 to obtain products (H-17).
Step (H-rg) converts compounds (H-17) according to process (D-f) to obtain products (H-18).
Step (H-h) converts compounds (H-18) according to process (C-f) to obtain products (H-19).
^ Step (H-i) converts compounds (H-20), (H-24), (H-27) and (H-30) according to process (D-h) to obtain products (H-21), (H-25), (H-28) and (H-31), respectively.
Step (H-j) converts compounds (H-18) according to process (C-e) 2g to obtain products (H-22).
Step (H-k) converts compounds (H-22) according to process (C-f) to obtain products (H-23).
Step (H-l) converts compounds (H-22) according to process (C-g) to obtain products (H-26). 30 Step (H-m) converts compounds (H-22) according to process (C-h) to obtain products (H-29).
Step (H-n) converts compounds (H-17) according to process (B-f) to obtain products (H-32).
Step (H-o) converts compounds (H-32) according to process (B-g) to obtain products (H-33).
M01414A - 29 - 902252 10 Compound (H-33) is converted to compounds (H-35), (H-38), (H-40), (H-42) according to the appropriate above-described processes. The alcohols of (H-34), (H-37), (H-38), and (H-41) may also be esterified with an acyl halide as hereinabove describe.
To prepare compounds of formula o cocf2x ' 15 CH, I 2 SiRjR2R 1-10 20 i.e., compounds wherein n is zero, m is one, Y is H, and X1 is H, Br, CI, F or R4, the following reaction scheme is utilized 25 Reaction Scheme I 30 SiRjRgRg (b) O -CRj-SiR^ C0CF„X' 1-11 1-12 1-13 35 M01414A - 30 - IE 902252 10 Step (I-a) converts compounds (1-11) according to process (A-a) to obtain products (1-12).
Step (I-b) converts compounds (1-12) according to process (A-b) to obtain products (1-13). The ketones may be reduced with sodium borohydride or sodium cyano borohydride by reaction in ethanol followed by hydrolysis with saturated ammonium chloride and the resulting alcohols esterified with an acyl halide (ClC(O)R with R being H or Cj 10 alkyl), in the presence of TEA (or neat pyridine) in a suitable solvent such as dichloromethane; both these reactions being effected according to well known and understood reaction conditions. 15 20 To prepare compounds of formula C-CF2X' sirjrgrg J-10 25 i.e., compounds wherein n is zero, m is one, Y1 is other than H, and X* is H, Br, CI, F or R4, the following reaction scheme is 30 utilized. 35 M01414A - 31 IE 902252 Reaction Scheme J h2n- H O Br j-11 -Br VH H n — o H -Br H G o -Br -H Br j-12 CHgSiRjRgRg j-13 1C / I' H 0 H CF2X' l ^ 2 H,N o 0 H -c-cf2x' CH^iR^.Rg CH2SiRjR2R3 CHjSiRjR^g 2C j-16 j-15 \ H OAc H OAc j-14 H OH 2£ h2n4o cf2x' q» Y40 ' CFoX 2 h _ v« -H ch2s irjrgrg j-17 H o CF„X1 ^H CH2SiRjR2R3 j-18 CHgSiRiR^g j-19 3C I h 0 yM-o ■cf2x' 35 CHgSiRjRjjRg J-20 M01414A - 32 - IE 902252 10 Step (J-a) converts compounds (J—11) to their stabase adduct as described in (B-a).
Step (J-b) converts compounds (J-12) to their silylated derivatives (J-13) using one equivalent of ICHjSiR^Rg after treatment of (J-12) with butyl lithium in ether at 0°C as in above-described silylating procedures.
Step (J-c) converts compounds (J-13) to (J-14) using procedures analogous to Step (B-c).
Step (J-d) converts compounds (J-13) to (J—15) using procedures analogous to Step (B-d).
Step (J-e) converts compounds (J-15) to (J-16) using procedures analogous to Step (B-e).
Step (J-f) converts compounds (J-16) to (J-17) using procedures 15 analogous to Step (B-f).
Step (J-g) converts compounds (J-17) to (J-18) using procedures analogous to Step (B-g).
Step (J-h) converts compounds (J-18) to (J-19) using procedures analogous to Step (B-h).
Step (J-i) converts compounds (J-19) to (J-20) using procedures analogous to Step (B-i). The alcohols (J-19) may also be esterified, as described above, with an acyl halide. 20 25 30 To prepare compounds of formula 0 o ch2 sirjrjrg 35 K-10 M01414A - 33 - IE 902252 wherein m is one, n is zero, Y is H, and X" is C0R9, C02R5, CONHRg or C0Re, is utilized. the following reaction scheme 10 15 20 25 30 35 M01414A - 34 - IE 902252 Reaction Scheme K o -OH ch3 K-11 o -oh CHgSiRjRgRg K-12 CH^SiRjRgRg K-13 cf2cor5 CHgSiRjRgRg K-18 cf2co2h CH2SiRjR2Rg K-17 CF2C02Et CH2SiRjR2R3 K-14 h 0 O •cf co r 3 2 5 cf conhr SI 9 cf2conhr5 CHjSiRjRgRg CH2SiR1R2R3 CH2SiR,R2R3 cf2cor# CH2SiRjR2R3 K-19 K-20 CF„CONHR. ch2sir,r2r3 K-21 K-22 cf2cor6 CHgSiRjRjjRg K-16 K-15 cf2cor9 CHjSiRjRjjRj K-16 M01414A - 35 - IE 902252 Step (K-a) converts 3-methylbenzyl alcohol (K-ll) to (K-12) by treatment with 3 equivalents of butyllithium at -20°C in diglyme, followed by treatment with 3 equivalents of ClSiRjR2R3 and triethylamine at room temperature, followed by ^ refluxing the extracted crude product in 90% aqueous methanol to obtain the desired silylated product.
Step (K-b) converts (K-12) to compounds (K-13) using procedures analogous to (C-b).
Step (K-c) converts (K-13) to compounds (K-14) using procedures analogous to (C-c).
Step (K-e) converts (K-14) to compounds (K-17) using procedures analogous to (C-e).
Steps (K-f) and (K-b) using procedures analogous to (C-f) and 15 (C-b) produce (K-19).
Steps (K-g) and (K-b) using procedures analogous to (C-g) and (C-b) produce (K-21).
Steps (K-h) and (K-b) using procedures analogous to (C-g) and (C-b) produce (K-23).
O A Steps (K-d) and (K-b) using procedures analogous to (C-d) and (C-b) produce (K-16). The alcohols of (K-14), (K-15), (K-18), (K-20), and (K-22) may also be esterified, as described above, with an acyl halide.
O C To prepare compounds of formula I represented by the subgeneric formula » 0 30 CH. i ' SiRjR2R3 35 L-10 M01414A - 36 - IE 902252 i.e., compounds wherein m is one, 5 n is zero, Y' is other than H, and X" is C0R9, C02R5, C0NHR5 or C0R6, the following reaction scheme is utilized. 10 15 20 25 30 M01414A - 37 - ac o > co 00 m CO o ro IE 902252 Reaction Scheme L (cont'd) 10 l-17 H OAc H OAc h oh F2C02Et CH.SiWs L-32 o cf2co2ec VH CHaSiRlR2R3 L-33 I' -o -cf2cor2 CH2siR,RA L-34 i' 15 cf2co2h CHjSiRjRjRj cf2cor9 cH2SiR,R2Rs 20 L-36 L-35 h oh h oh h oh y— o cf2co2r5 O cfjconhrg 25 cH2SiR,R2Rs y—o cfoc0r„ CHjSiRjRgRj CHjSiRjRjRj L-37 L-39 30 I' 1' L-41 C^SiR^R, I' h 0 o -cf2co2r5 H 0 O 35 CH2SiR,RsR3 -cf2conhr5 CHjSiRjRjRj cf2cora CH^iR^ L-38 L-40 L-42 M01414A - 39 - IE 902252 10 Step (L-a) convert (L-ll) to (L-12) according to a process analogous to (B-a).
Step (L-b) converts (L-12) to (L-13) by treating the stabase adduct with one equivalent of butyllithium in diethyl ether at 0°C followed by reaction with one equivalent of CH3I.
Step (L-c) converts (L-13) to (L-14) using procedures analogous to (D-c).
Step (L-d) converts (L-14) to (L-15) using procedures analogous to (K-a).
From (L-15), using procedures analogous to procedures (D-d), (D-e), (D-f), (D-g) and (D-i), there is produced (L-19) and (L-22).
From (L-18), using procedures analogous to (K-D) there is produced (L-20).
From (L-19) and (L-22), using the procedures analogous in the obtention of compounds (D-20), (D-24), (D-27) and (D-30), there is obtained compounds (L-25), (L-28), (L-31) and (L-21). Similarly starting with compound (L—17) and by analogously 20 applying the chemical process reactions performed on (D-6) and its resulting subsequent derivatives to prepare compounds (D-34), (D-37), (D-39) and (D-41) there is also produced compounds (L-35), (L-38), (L-40) and (L-42). The alcohols L-34, L-37, L-39, L-41 may also be esterified as hereinabove described.
As illustrated in structure (B-12) the stabase moiety is depicted as 30 V N- 25 35 kSi - / \ M01414A - 40 - IE 902252 For convenience and following generally accepted practice, that moiety is thereafter abbreviated as In all instances wherein the abbreviated form is utilized it is fully intended to designate that moiety as depicted in structure (B-12).
Having generically described the methods for the 15 preparation of the compounds of this invention, the following specific examples illustrate the chemistry and techniques by which the synthesis may be effected. 5 20 25 30 35 M01414A - 41 - IE 902252 EXAMPLE 1 2.2«2-Trifluoro-l-(3-trimethylsilylphenyl) ethanone 5 Step A: 3-Trimethylsilyl-bromobenzene A mixture of 1,3-dibromobenzene (25.0 g, 106.4 mmol) and trimethylsilylchloride (11.6 g, 106.4 mmol) in diethyl ether ^ (50 ml) was added dropwise in 1? hours on magnesium (2.59 g, 106.4 mmol) in diethyl ether (25 ml). Then the mixture was refluxed for 18 hours, cooled to 0°C, treated with 4N HC1 (75 ml). The organic layer was separated, washed with water, brine, dried over MgSO^ and concentrated. 3-Trimethylsilyl-bromobenzene was obtained by fractional distillation as a colorless oil (13.4 g, 55% yield, b.p.: 55-62°C (0.8 mmHg).
Step B: 20 2.2.2-Trifluoro-l-(3-trimethylsilylphenyl) ethanone To a solution of 3-trimethylsilyl-bromobenzene (7.62 g, 33.3 mmol) in diethyl ether (35 ml) was added at 0°C 1.5M n-butyllithium in hexane (22.2 ml, 33.3 mmol) over 10 min. Then o c the mixture was allowed to react 15 min at room temperature, cooled to -78°C and ethyltrifluoroacetate (14.2 g, 100 mmol) was added over 5 min. Then the mixture was allowed to react 15 min at -78°C, the cooling bath was removed and when the 2Q temperature rose to 0°C 3N HC1 (35 ml) was added dropwise. The organic layer was separated , washed with water, brine, dried over MgSO^ and concentrated. Chromatography (silica gel, cyclohexane/diethyl ether: 90/10) followed by distillation under reduced pressure afforded the expected compound as a 35 colorless oil (4.32 g, 53% yield), b.p. 120°C, Rf: 0.28 (cyclohexane/diethyl ether: 95/5).
M01414A - 42 - /e 902252 EXAMPLE 2 l~f(4-Methoxy-3-trimethylsilyl)phenyl1-2,2,2-trifluoroethanone 5 Step A: 4-Bromo-3-trimethylsilvlanisole To a solution of 2,4-dibromoanisole (13.3 g, 50 mmol) in diethyl ether (50 ml) at 0°C was added over 20 min 1.5M ^ butyllithium (33.4 ml) and the reaction was allowed to react 15 min at 0°C. Then trimethylsilylchloride (5.43 g, 50 mmol) in diethyl ether (20 ml) was added over 10 min and the resulting mixture was stirred 18 hours at room temperature. At 0°C 3N HC1 (50 ml) was added and the organic layer was separated, washed with water, brine, dried over MgSO^ and concentrated. 4-Bromo-3-trimethylsilylanisole was purified by chromatography on silica gel (eluted with cyclohexane) as a colorless oil. 20 Step B: 1-[(4-Methoxy-3-trimethylsilyl)phenyl1-2.2.2-trifluoroethanone The title compound was prepared as described in Step B of Example 1. Chromatography on silica gel (cyclohexane/diethyl ether: 95/5) afforded a colorless oil (59% yield). 25 EXAMPLE 3 1—f(4—Hydroxy-3—trimethylsilyl)phenyl1—2,2,2—trifluoroethanone 30 Step A: 4-Bromo-3-trimethylsilylphenol To a solution of 2,4-dibromophenol (8.0 g, 31.75 mmol) in diethyl ether (35 ml) at 0°C was added over 50 min 1.5M butyllithium (42.3 ml) and the mixture was stirred 2? hours at room temperature. At 0°C 3N HC1 (100 ml) was added, the organic M01414A - 43 - 902252 layer was separated, washed with water, brine, dried over MgSO^ and concentrated. The crude product was dissolved in 90% aqueous methanol (50 ml) and refluxed 2 hours, then the solvents were removed and the title compound was purified by 5 chromatography on silica gel (10% ethyl acetate in cyclohexane ).
Step B: 1-f(4-Hydroxy-3-trimethvlsilvl)phenyll~2.2.2-trifluoroethanone 10 To a solution of 4-bromo-3-trimethylsilylphenol (2.54 g, 10 mmol) in diethyl ether (10 ml) at 0°C was added 1.5M butyllithium (13.4 ml) over 10 min and the mixture was stirred at 0°C 15 min. At -78°C was added ethyl trifluoroacetate (5.68 g, 40 mmol) in diethyl ether (10 ml), then the mixture 15 was allowed to warm up to room temperature and was stirred 1 hour. At 0°C 3N HCl (20 ml) was added, the organic layer separated, washed with water and concentrated. The crude product was dissolved in tetrahydrofuran (20 ml) and stirred 2q 1 hour with aqueous sodium hydrogen carbonate (10 ml). The mixture was extracted with diethyl ether and the extract washed with water, brine, dried over MgSO^ and concentrated. The title compound was purified by chromatography on silica gel (20% ethyl acetate in cyclohexane), followed by recrystallization in 25 CCl^. m.p. 178°C, Rf: 0.50 (cyclohexane/ diethyl ether: 50/50).
EXAMPLE 4 l-(3,5-Bis-trimethylsilylphenyl)-2.2,2-trifluoroethanone 30 Step A: 3,5-Bis-trimethvlsilyl-bromobenzene A mixture of 1,3,5-tribromobenzene (10.0 g, 31.75 mmol) and trimethylsilylchloride (6.90 g, 63.50 mmol) in diethyl M01414A - 44 - /e 9(>22S2 ether (35 ml) was added dropwise in 1 hour on magnesium (1.55 g, 63.50 mmol) in diethyl ether (20 ml). Then the mixture was refluxed 18 hours, cooled to 0°C, treated with 4N HC1 (50 ml). The organic layer was separated, washed with water, 5 brine, dried over MgSO^ and concentrated. 3,5-Bis-trimethyl- silyl-bromobenzene was purified by chromatography on silica gel (eluted with heptane) as a colorless oil (5.39 g, 56% yield).
Step B: l-(3.5-Bis-trimethylsilylphenyl)-2,2,2-trifluoroethanone The title compound was prepared as described in Step B of Example 1 in 35% yield, b.p. 170°C (26 mmHg). 15 EXAMPLE 5 Ethyl-2,2-difluoro-3-keto-3-(3-trimethylsilyl)phenylpropionate 20 Step A: 3-Trimethylsilylbenzylalcohol To a solution of 3-bromobenzylalcohol (9.35 g, 50 mmol) in diethyl ether (50 ml) at 0°C was added dropwise 1.5M butyl-lithium (66.7 ml) and the mixture was stirred 30 min. Then trimethylsilylchloride (11.39 g, 105 mmol) in diethyl ether (50 ml) was added dropwise and the mixture was stirred at room temperature 18 hours. The reaction mixture was treated with ice 2Q water (100 ml) and the organic layer extracted, washed with water, brine, dried over MgSO^ and concentrated. The crude product was dissolved in 90% aqueous methanol (100 ml) and refluxed 1 hour. The solvents were removed and 3-trimethyl-silylbenzylalcohol was purified by distillation. 35 M01414A - 45 - IE 902252 Step B: 3-Trimethylsilylbenzaldehvde To a mixture of 3-trimethylsilylbenzylalcohol (3.60 g, 5 20 mmol) and pyridium dichromate (11.29 g, 30 mmol) in dichloromethane (60 ml) at 0°C was added 3l molecular sieve powder (16 g) and anhydrous acetic acid (2 ml). Then the reaction was allowed to react 30 min at room temperature, stirred 20 min with celite (10 g), filtered and evaporated ^ under reduced pressure. The residue was treated with diethyl ether (50 ml), filtered through MgSO^ and concentrated. 3-trimethylsilylbenzaldehyde was purified by distillation. 15 Step Cs Ethyl-2.2-difluoro-3-hvdroxy-3-(3-trimethylsilyl)phenyl-propionate A solution of 3-trimethylsilylbenzaldehyde (1.78 g, 20 10 mmol) and ethyl bromodifluoroacetate (2.23 g, 11 mmol) in tetrahydrofuran (10 ml) was added dropwise on zinc wool (7.85 g, 12 mmol) in refluxing tetrahydrofuran (10 ml). Then the reaction was allowed to react 1 hour, cooled, hydrolysed with a saturated ammonium chloride solution (20 ml) and diluted with diethyl ether (20 ml). The organic layer was washed with brine, dried over MgSO^ and concentrated. The title compound was purified on silica gel (20% ethyl acetate in cyclohexane). 20 Step D: Ethyl-2,2-difluoro-3-keto-3-(3-trimethylsilyl)phenylpropionate The title compound was prepared as described in Step B and purified by distillation. 35 M01414A - 46 - 902252 EXAMPLE 6 2.2-Di fluoro-3-ke to-3-(5-ni trile-3-trimethyls i1y1)phenyl propanoic acid Step A: 3.5-Dibromo-N.N-(1.1,4,4-tetramethyl-l,4-disilethylene)aniline To a solution of 3,5-dibromoaniline (25,10 g, 100 mmol) in tetrahydrofuran (100 ml) at -30°C was added 1.5M butyllithium (66.67 ml). Then at -78°C was added a solution of 1,1,4,4-tetramethyl-1,4-dichlorosilethylene (21.50 g, 100 mmol) in tetrahydrofuran (100 ml) and the mixture was allowed to warm at room temperature and stirred 1 hour. The mixture was poured into water (200 ml), diluted with diethyl ether (100 ml) and the ether layer separated. The aqueous layer was washed twice with diethyl ether and the etheral extracts combined, dried over MgSO^ and the solvents removed under reduced pressure. The title compound was recrystallized from hexane.
Step B: 3-Bromo-5-trimethylsilvl-N«N-(1,1,4,4-tetramethyl-l,4-disilethylene)aniline The title compound was prepared as described in Step A of Example 1, except for hydrolysis which was made with a saturated ammonium chloride solution. Purification was achieved by recrystallization from hexane.
M01414A - 47 - IE 902252 Step C: 3-Trimethylsilyl-5-f N.N-(1«1«4.4-tetramethvl-l,4-disilethyl-ene)laminobenzylalcohol 5 To a solution of 3-trimethylsilyl-5-[N,N-(1,1,4,4-tetra- methyl-1,4-disilethylene)]aminophenyl magnesium bromide prepared from 3-bromo-5-trimethylsilyl-N,N-(1,1,4,4-tetra-methyl-1,4-disilethylene)aniline (11.26 g, 30 mmol) and magnesium (0.73 g, 30 mmol) in diethyl ether (60ml) was added paraformaldehyde (0.99 g, 33 mmol). Then the mixture was refluxed 18 hours, cooled to 0°C and treated with a saturated ammonium chloride solution (50 ml). The ether layer was separated, washed with water, brine, dried over MgSO^ and ^0 concentrated. The title compound was recrystallized from diethyl ether-hexane.
Step D: 3-Trimethylsilyl-5-f N«N-(1,1,4,4-tetramethyl-l,4-disilethyl-20 ene)1aminobenzaldehyde The title compound was prepared as described in Step B of Example 5 and recrystallized from diethyl ether hexane. 25 Step E: Ethy1-2,2-difluoro-3-hvdroxy-3-f3-trimethylsilyl-5-f N.N- (1,1,4,4-tetramethyl-l,4-disilethylene)1 amino 1 phenyl propionate 2Q The title compound was prepared as described in Step C of Example 5 and recrystallized from diethyl ether hexane. 35 M01414A - 48 IE 902252 Step F: Ethyl-2,2-difluoro-3-acetoxy-3-(3-trimethylsilyl-5-amino)phenyl propionate 5 To a solution of ethyl-2,2-difluoro-3-hydroxy-3-[3- trimethylsilyl-5-[N,N-(1,1,4,4-tetramethyl-l,4-disil-ethylene)]amino]phenyl propionate (5.51 g, 12 mmol) and triethylamine (1.31 g, 13 mmol) in tetrahydrofuran (15 ml) at 0°C was added acetyl chloride (0.94 g, 12 mmol). Then the ^ mixture was stirred 1 hour at room temperature, cooled to 0°C, treated slowly with 10% HC1 in ethanol (20 ml) followed by stirring for 3 hours at room temperature. The solvents were removed under reduced pressure and the residue partitioned between diethyl ether and water. The acidic aqueous layer was separated and made basic, then extracted twice with diethyl ether. The organic extract was dried over MgSO^ and concentrated and the product was purified by conversion to its hydrochloride salt. 20 Step G: Ethyl-2.2-difluoro-3-acetoxy-3-(3-trimethylsilyl-5-nitrile)-phenylpropionate o c To a solution of ethyl-2,2-difluoro-3-acetoxy-3-(3-trimethylsilyl-5-amino)phenyl propionate hydrochloride (3.96 g, 10 mmol) in 0.5N HCl (20 ml) at 0°C was added a solution of sodium nitrite (0.69 g, 10 mmol) in water (5 ml), the 2Q temperature being kept at 0-5°C by the addition of cracked ice. Then the mixture was cautiously neutralized by adding dry sodium carbonate. The resulting mixture was added dropwise to a solution of copper cyanide (0.90 g, 10 mmol) in ice water (10 ml) and toluene (20 ml) while vigorous stirring was 35 maintained and the temperature being kept at 0~5°C. Then the temperature was held at 0-5°C for 30 min, allowed to rise to M01414A - 49 - IE 902252 room temperature and stirring was continued for 3 hours. Then the toluene layer was separated, washed twice with water, brine, dried over MgSO^ and concentrated under reduced pressure. The title compound was purified on silica gel (30% 5 ethyl acetate in cyclohexane).
Step H: 2,2-Difluoro-3-hvdroxy-3-(3-trimethylsilyl-5-nitrilephenyl-propionic acid 10 To a solution of ethyl-2,2-difluoro-3~acetoxy-3-(3-tri-methylsilyl-5-nitrile)phenyl propionate (1.85 g, 5 mmol) in 1,2-dimethoxyethane (8 ml) and water (2 ml) was added lithium hydroxide (0.36 g, 15 mmol) and the mixture was stirred 2 hours at room temperature. Then the solvent was removed under reduced pressure. The crude product was dissolved in water (20 ml) and extracted twice with diethyl ether. Then the aqueous layer was made acidic with IN HCl and extracted with dichloromethane. The 20 organic layer was dried over MgSO^ and concentrated under reduced pressure. The title compound was recrystallized from diethyl ether.
Step I: ^ 2,2-Difluoro-3-keto-3-(3-trimethvlsilyl-5-nitrile)phenyl-propionic acid The title compound was prepared as described in Step B of 2Q Example 5 and recrystallized from diethyl ether. 35 M01414A - 50 - IE 902252 10 EXAMPLE 7 1,1.1-Trifluoro-3-(3-trimethylsilyl)phenylpropanone Step A: 3-Trimethvlsi.lylbenzylethyl ether To a solution of 3-trimethylsilylbenzylalcohol (3.60 g, 20 mmol) in tetrahydrofuran (40 ml) at 0°C was added dropwise 1.5 M butyllithium (13.3 ml) and the mixture was stirred for 10 minutes. Then iodobutane (3.12 g, 20 mmol) in tetrahydrofuran (20 ml) was added dropwise and the mixture was stirred at room temperature for 3 hours. The reaction mixture was treated with water (100 ml) and the crude product was extracted twice with diethyl ether (100 ml). The organic layer was washed with brine, dried over MgSO^, concentrated and 3-trimethylsilyl-benzylethyl ether was purified by distillation. 20 Step B: 1,1,1-Trifluoro-3-(3-trimethylsilyl)phenylpropanone 25 To a suspension of lithium (0.42 g, 60 mmol) in tetrahydrofuran (10 ml) at -10°C was added dropwise 3-trimethyl-silylbenzylethyl ether (2.08 g, 10 mmol) in diethyl ether (10 ml). Then the mixture was allowed to react 1 hour at -10°C and added dropwise to a solution of ethyl trifluoroacetate (2.84 g, 20 mmol) in diethyl ether (20 ml) at -78°C. Then the cooling bath was removed and the mixture was allowed to warm to room temperature, treated with 3 N HCl (20 ml). The organic layer was separated, washed with water, brine, dried over MgSO^ and concentrated under reduced pressure. Chromatography on silica gel (10% diethyl ether in cyclohexane), followed by 35 distillation under reduced pressure, afforded the expected product. 30 M01414A - 51 - IE 902252 EXAMPLE 8 1,1.1-Trifluoro-3-(3-trimethvlsilvl-5-amino)phenylpropanone hydrochloride 5 Step A: 3-Trimethylsilyl-5-r N.N-(1.1.4.4-tetramethyl-l.4-disilethyl-ene)laminobenzylbromide ^ To a solution of 3-bromo-5-trimethylsilyl-[N,N-(1,1,4,4- tetramethyl-1,4-disilethylene)aniline (3.86 g, 10 mmol) in diethyl ether (10 ml) at 0°C was added 1.5M butyllithium (6.67 ml). Then the mixture was stirred 15 min, cooled to -78°C and treated with dibromomethane (1.74 g, 10 mmol) in diethyl ether (5 ml). Stirring was continued 30 min at -78°C, then the temperature was allowed to rise to room temperature and stirring was continued for 1 hour. To the mixture was added a saturated ammonium chloride solution (20 ml) and the organic 20 layer separated, washed with water, brine, dried over MgSO^ and concentrated under reduced pressure. The title compound was purified by recrystallization from hexane.
Step B: p C 1.1.1-Trifluoro-3-(3-trimethylsilvl-5-amino)phenylpropanone hydrochloride To a solution of 3-trimethylsilyl-5-[N,N-(1,1,4,4-tetra-2Q methyl-1,4-disilethylene)]aminobenzyl magnesium bromide prepared from 3-trimethylsilyl~5-[N,N-(1,1,4,4-tetramethyl-l,4-disilethylene) ]aminobenzylbromide (2.00 g, 5 mmol) and magnesium (0.12 g, 5 mmol) in diethyl ether (10 ml) at -78°C was added ethyltrifluoroacetate (1.42 g, 10 mmol) over 5 min. 35 Then the cooling bath was removed and the mixture was allowed to warn to 0°C, treated slowly with 10% HCl in ethanol (10 ml), M01414A - 52 - IE 902252 followed by stirring for 3 hours at room temperature. The solvents were removed under reduced pressure and the residue partitioned between diethyl ether and water. The acidic aqueous layer was separated and made basic, then extracted twice with 5 diethyl ether. The ether extract was dried over MgSO^ and concentrated and the title compound was purified by conversion to its HCl salt.
EXAMPLE 9 10 Ethyl-2,2-difluoro-3-keto-4-(3-trimethylsilyl)phenyl butanoate Step A: 3-Trimethylsilylbenzvlbromide A mixture of 3-trimethylsilyltoluene (3.28 g, 10 mmol), N-bromosuccinimide (1.78 g, 10 mmol) and benzoylperoxide (10 mg) in CCl^ (20 ml) was stirred under reflux for 3 hours, 2q then cooled and filtered. The solvent was removed under reduced pressure and 3-trimethylsilylbenzylbromide was purified by distillation.
Step B: 25 2-(3-Trimethyls ilyl)phenylethanol The title compound was prepared as described in Step C of Example 6 and recrystallized from diethyl ether - hexane. 30 Step C: 2-(3-Trimethylsilyl)phenylethanal The title compound was prepared as described in Step B of Example 5 and purified by distillation. 35 M01414A - 53 - IE 902252 Step D: Ethyl-2,2-difluoro-3-hydroxy-4-(3-trimethylsilyl)phenyl butanoate 5 The title compound was prepared as described in Step C of Example 5.
Step E: Ethyl-2,2-difluoro-3-keto-4-(3-trimethylsilyl)phenyl butanoate 10 The title compound was prepared as described in Step B of Example 5 and purified by distillation. 15 EXAMPLE 10 Ethyl-2,2-dif luoro-3-keto-4-(3-triiaethylsilvl-5-aiiiino)phenyl butanoate hydrochloride 20 Step A: 2-f 3-Trimethylsilvl-5-[N.N-(1«1,4,4-tetramethyl-l,4-disilethyl-ene)amino 11 phenyl ethanol The title compound was prepared as described in Step C of 25 Example 6.
Step B: 2-f 3-Trimethvlsilvl-5-fN.N-(1.1,4,4-tetramethyl-l.4-disilethvl-2Q ene)amino 11 phenyl ethanal The title compound was prepared as described in Step B of Example 5. 35 M01414A - 54 - IE 902252 Step C: Ethyl-2.2-difluoro-3-hvdroxy-4-f3-trimethylsilyl-5-f N.N- (1,1,4,4-tetramethyl-l,4-disilethylene)amino1Iphenyl butanoate 5 The title compound was prepared as described in Step C of Example 5.
Step D: Ethyl-2,2-difluoro-3~keto-4-(3-trimethylsilyl-5-amino)phenyl butanoate hydrochloride The title compound was prepared by following the procedure described in Step B of Example 5 and purified to its jg hydrochloride salt by removing the protecting amino group with 10% HCl in ethanol.
EXAMPLE 11 20 1,1,l-Trifluoro-2-(3-trimethylsilylmethyl)phenyl ethanone Step A: 3-Trimethylsilylmethvlphenylbromide O C The title compound was prepared as described in Step A of Example 1.
Step B: 2Q 1.1,l-Trifluoro-2-(3-trimethvlsilylmethyl)phenyl ethanone The title compound was prepared as described in Step B of Example 1. 35 M01414A - 55 - IE 902252 EXAMPLE 12 1.1.1-Trifluoro-2-(3-trimethvlsilylmethyl-5-amino)phenyl ethanone hydrochloride 5 Step A: 3-Trimethylsilvlmethyl-5-fN,N-(1,1,4,4-tetramethyl-l,4-disilethylene 1 amino phenylbromide To a solution of 3,5-dibromo-N,N-(1,1,4,4-tetramethyl-l,4-disilethylene)aniline (7.86 g, 20 mmol) in diethyl ether (20 ml) at 0°C was added 1.5M butyllithium in hexane (13.3 ml) over 10 min. Then the mixture was stirred 15 min at 0°C and iodomethyltrimethylsilane (4.28 g, 20 mmol) in diethyl ether (10 ml) was added dropwise. The mixture was stirred 3 hours at room temperature and treated with a saturated ammonium chloride solution (20 ml). The ether layer was separated, washed with water, brine, dried over MgSO^ and concentrated under reduced 20 pressure. The title compound was recrystallized from hexane.
Step B: 1.1.l-Trifluoro-2-(3-trimethylsilylmethvl-5-amino)phenyl ethanone hydrochloride 25 The title compound was prepared by following the procedure described in Step B of Example 1. After hydrolysis and removing of the organic layer, the aqueous layer was made basic and 2Q extracted twice with dichloromethane. The dichloromethane extract was dried over MgSO^, concentrated under reduced pressure and the title compound was purified by conversion to its hydrochloride salt. 35 M01414A - 56 - IE 902252 EXAMPLE 13 Ethyl-2,2-di fluoro-3-keto-3-(3~trimethy1s i1ylmethy1)phenyl propionate Step A: 5 3-Trimethylsilylmethvlbenzvlalcohol To a solution of 3-methylbenzylalcohol (6.10 g, 50 mmol) in anhydrous diglyme (200 ml) at -78°C was added 1.5M butyllithium (100 ml) over 20 min. The resulting mixture was allowed ^ to warm to -20°C and stirred for 30 min. Then a mixture of trimethylchlorosilane (19.0 g, 175.0 mmol) and triethylamine (5.05 g, 50 mmol) was added and the final solution was stirred at room temperature for 3 hours. The reaction mixture was treated with ice water (200 ml), extracted three times with diethyl ether (100 ml) and the extracts washed twice with water, brine, dried over MgSO^ and concentrated. The crude product was dissolved in 90% aqueous methanol (200 ml) and refluxed for 1 hour. Then the solvents were removed and 3-tri-20 methylsilylmethylbenzylalcohol was purified by fractional distillation.
Step B: 3-Trimethvlsilylmethylbenzaldehyde 25 The title compound was prepared as described in Step B of Example 5.
Step C: 2Q Ethyl-2.2-difluoro-3-hvdroxv-3-(3-trimethylsilylmethyl)phenyl propionate The title compound was prepared as described in Step C of Example 5. 35 M01414A - 57 - 902252 Step D: Ethyl-2,2-difluoro-3-keto-3-(3-trimethylsilylmethvl)phenyl propionate The title compound was prepared as described in Step B of 5 Example 5.
EXAMPLE 14 Ethyl-2.2-difluoro-3-keto~3-(3-trimethylsilylmethyl-5-amino) phenyl propionate hydrochloride Step A: 3-Bromo-5-f N,N(1,1,4,4-tetramethyl-l,4-disilethylene)amino 1-^5 toluene To a solution of 3,5-dibromo-N,N-(1,1,4,4-tetramethyl-l,4-disilethylene)aniline (19.65 g, 50 mmol) in diethyl ether (50 ml) at 0°C was added 1.5M butyllithium (33.3 ml) over 20 15 min. Then the mixture was stirred for 15 min and iodomethane (7.10 g, 50 mmol) in diethyl ether (15 ml) was added over 15 min at 0°C. The mixture was stirred 1 hour at 0°C and was allowed to warm to room temperature and stirred for 3 hours. Then the reaction mixture was poured into ice water (100 ml). The organic layer was separated, washed with brine, dried over MgSO^ and concentrated. The title compound was recrystallized from hexane. 30 Step Bi 3-Methyl-5~f N,N(1,1,4,4-tetramethyl-l,4-disilethylene)1-aminobenzyl alcohol The title compound was prepared as described in Step C of 35 Example 6.
M01414A - 58 - IE 902252 Step C: 3-Trimethylsilylmethvl-5-f N,N(1,1,4,4-tetramethyl-l,4-disilethylene) Taminobenzyl alcohol 5 The title compound was prepared as described in Step A of Example 13 and recrystallized from hexane.
Step D: 3-Trimethylsilylmethyl-5-f N,N(1,1,4,4-tetramethyl-l,4-^ disilethylene)laminobenzaldehyde The title compound was prepared as described in Step D of Example 6. 15 Step E: Ethvl-2,2~di fluoro-3-hvdroxy-3-f 3~trimethyls i1ylmethy1-5-f N, N-(1,1,4,4-tetramethyl-l,4-disilethylene)1 amino 1phenylpropionate 20 The title compound was prepared as described in Step E of Example 6.
Step F: Ethvl-2.2-difluoro-3-keto-3-(3-trimethvlsilylmethyl-5-amino)- p C phenyl propionate hydrochloride The title compound was prepared as described in Step D of Example 10. 30 35 M01414A - 59 - IE 902252 It is now established that Alzheimer's disease and other senile degenerative diseases are characterized by a selective loss in the cerebral cortex of choline acetyltransferase, the enzyme responsible for the biosynthesis of acetylcholine. There ^ also exists a good correlation between memory impairment or dementia and the decrement in cholinergic transmission. Thus, impaired cholinergic transmission in the central nervous system may be, at least in part, responsible for the symptomatology of Alzheimer's disease and senile dementia. In support to these conclusions such compounds as physostigmine and 1,2,3,4-tetra-hydro-9-aminoacridine (THA), compounds which prevent the catabolism of acetylcholine have found a place in the treatment of Alzheimer's and other senile degenerative diseases. Indeed, 15 it has been recognized that the extent of improvement of cognitive functions has been closely related to the degree of inhibition of acetylcholinesterase.
The compounds of Formula I are pharmacologically active 20 agents capable of inhibiting acetylcholinesterase as demonstrable in standard biological in vitro and in vivo test procedures. Indeed, based upon standard laboratory procedures, it is to be shown that the compounds of Formula I are potent and selective, quasi irreversible inhibitors of acetylcholin- 25 esterase capable of demonstrating advantages over the prior art, particularly physostigmine, in their use in the treatment of Alzheimer's disease and senile dementia. The compounds, in general, will exert their acetylcholinesterase inhibitory 2q properties within the dose range of about 0.01 mg to 5 mg per kilogram of body weight for the preferred compounds.
For pharmacological end-use applications, the compounds of Formula I are preferentially administered in the form of their 20 pharmaceutically acceptable acid addition salts. Of course, the effective dosage of the compounds will vary according to the M01414A - 60 - 902252 individual potency of each compound employed, the severity and nature of the disease being treated and the particular subject being treated. In general, effective results can be achieved by administering a compound at a dosage of about 0.01 mg to about 20 mg per kilogram of body weight per day, administered systemically. Therapy should be initiated at lower dosages. The dosage thereafter may be administered orally in solid dosage forms, e.g., capsules, tablets, or powders, or in liquid forms, e.g., solutions or suspensions. The compounds may also be injected parenterally in the form of sterile solutions or suspensions. Solid oral forms may contain conventional excipients, for instance: lactose, sucrose, magnesium stearate, resins, and like materials. Liquid oral forms may contain various flavoring, coloring, preserving, stabilizing, buffering, solubilizing, or suspending agents. If desired, additives, such as saline or glucose may be added to make the solutions isotonic. 10 20 As is true for most classes of compounds suitable for use as therapeutic agents, certain subgeneric groups and certain specific compounds are preferred. In this instance those compounds wherein Rj, R2 and R3 are all methyl or ethyl or mixtures thereof are preferred, and wherein one of Rx, R2 and R3 25 is a long-chain (8 to 10 carbon atoms) alkyl. Preferred compounds are those wherein X is F, or hydrogen, or alkyl, or C0R9 wherein R9 is alkyl, or C02R5 wherein R5 is H or alkyl, or CONHRg wherein R5 is H or alkyl. Preferred groups of compounds are also those wherein m is one and n is zero; n is one and m is zero or when both are zero. It is preferred that Y be hydrogen, alkoxy or SiRjR2R3 with the preferred SiRjR^ moieties being as described for the SiRjR2R3 at the 3-position of depicted Formula I, although when any specific compound is a 2g bis-SiR,R2R3 both moieties need not be identified. 30 M01414A - 61 - IE 902252 Specifically preferred compounds are those charted below as follows: 3-position SiRjRgRg m n X 5 1. ch3, ch3, ch3 0 0 F H 2.
CH3, Et, Et 0 0 F H 3.
Et, Et, Et 0 0 F h 4.
Et, Et, CH3 0 0 F h 10 5.
CH3, CH3, Et 0 0 F H 6. ch3, ch3, ch3 0 0 F 5 7. octyl, CH3, CH3 0 0 F H 8. ch3, ch3, ch3 1 0 F H 15 9. ch3, ch3, ch3 0 1 F H 10.
CHg, CH3, CH3 0 0 H H 11. ch3, ch3, ch3 0 0 CHg H 12.
CHg, CHg, CHg 0 0 -COCHg H 20 13.
CHg, CHg, CHg 0 0 -COOCHg H 14.
CHg, CHg, CHg 0 0 -CONHCHg H (Y) 25 30 35 M01414A - 62 -

Claims (3)

IE 902252 We claim 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 1. A compound of the formula H <^«>r_(CH2)n-Q-CF2X
1. 12. The specific compounds of Claim 2 as
2. Following chart: 3 4
3. -position SiRjR2R3 m n X 5 ch3,ch3,ch3 0 0 F H 6 CH3, Et, Et 0 0 F H 7 Et, Et, Et 0 0 F H 8 n Et, Et, CH3 0 0 F H 9 10 11 CH3,CH3,Et ch3, ch3, ch3 0 0 0 0 F F H 5- 12 octyl, CH3, CH3 0 0 F H 13 ch3, ch3, ch3 1 0 F H 14 ch3, ch3, ch3 0 1 F H 15 ch3,ch3,ch3 0 0 H H 1 6 ch3, ch3, ch3 0 0 ch3 H 17 ch3, ch3, ch3 0 0 -c0ch3 H 18 19 ?n ch3, ch3, ch3 0 0 -cooch3 h ch3, ch3, ch3 0 0 -conhch3 H (Y) 21 wherein Et is ethyl and CH3 is methyl. M01414A - 65 - IE 902252 PRQr SS CLAIMS 1 13. A process for preparing a compound of the formula R3-SiR1 10 i 11 R2 12 13 and the pharmaceutically acceptable salts thereof, wherein each 14 of m and n is zero or one with the proviso that the sum of m 15 and n is less than two, 16 Q is ~C~> or -CH with R being H or C, ,0 alkyl 0 OH 0-C-R II 0 is X' or X" with X' being H, Br, CI, F or R4 and X'1 being C0R9, C02R5, C0NHR5 or C0R6, R2, R3 and R4 each being Cj ,0 alkyl, or (CH2)p aryl, with p being zero, one or two, is H, Cj 10 alkyl, phenyl, benzyl or phenethyl, is Cj l0 alkyl, phenyl, benzyl or phenethyl, is (NHCHR7C(0) )qRg with R7 being the residue of any natural occurring a-amino acid, q is one to four and Rg is OR5 or NHR5, 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Ri. 32 M01414A - 66 - IE 902252 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 Y is H, OH, Cj e alkyl, C,^ alkoxy, hydroxy Cj^ alkyl, amino C,. alkyl, NH„, azido, CN, CO„R,, CORq, -SO,H, Br, CI, F or -(CH2)xSiR,R2R3 with x being zero, one or two, Y' is OH, Cj^ alkyl, C}^ alkoxy, hydroxy Cj^ alkyl, amino Cj 6 alkyl, NH2, azido, CN, C02R5, C0R9, -S03H, Br, CI, F or -(CH2)xSiR,R2R3 with x being zero, one or two, which comprises (a) in the instance of preparing compound of the sub- generic formula 0 (CH2)n-C-CF2X' (2) (CH2)m SiRjR2R3 which comprises forming a lithio derivative of a compound of the formulae and (3) I z m SiRjR2R3 CH„0Et (4) S iRjRjRj and reacting said lithio derivative with an acid (as its lithio salt), ester or acid chloride of the formulae X'CFjCOgR or X4CF2C0C1 wherein R is H or Ct^ alkyl; M01414A - 67 - 902252 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 (b) in the instance of preparing a compound of the sub-generic formulae 0 II (CH2)m-C-CF2X' and (5) (CH2)n-C-CF2X" (6) m z m SiRjRgRg SiRjR2R3 which comprises oxidizing compounds of the formulae OH I (CH2)nCH-CF2X' and (7) C CHo ) m 4 tn S iRjRgRg OH I (CH2)nCH-CF X" (8) SiR,R2R3 (c) in the instance of preparing a compound of the subgeneric formula OH I (CH2)nC-CF2X' (9) SiR,R2R3 which comprises chemically reducing a compound of Formula (2) above, M01414A - 68 - IE 902252 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 (d) in the instance of preparing a compound of the sub-generic formulae y! oh I (ch2)nch-cf2x' and (10) Wn, oh (ch2)nch-cf2x" (11) I £ Ell SiRjRjRj SiRjRgRg which comprises hydrolyzing a compound of the formulae 0c(0)r I (gh2)nch-cf2x' and 0c(0)r (ch2)nch-cf2xn { £> Ol sir,r2r3 (12) (CH2)m SiRjR2R3 (13) (e) in the instance of preparing a compound of the sub-generic formula 0c(0)r I (ch2)nch-cf2x (14) SiRjR2R3 M01414A - 69 - IE 902252 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 which comprises esterifying a compound of the formula oh I (ch2) ch-cf2x (15) SiRjRgRj with an acyl halide, (f) in the instance of preparing a compound of the sub-generic formula oh I (ch2)„ch-cf2co2h (16) SiR,R2R3 the process which comprises the hydrolysis of a compound of the formula h oh I (ch2)nch-cf2c0 alkyl h (17) W. SiRjR2R3 by reaction with lithium hydroxide in 80X ethylene glycol dimethyl ether. M01414A - 70 - 902252 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 (g) in the instance of preparing a compound of the sub-generic formula oh I (ch2)nch-cf2c02r9 (18) SiR,R2R3 which comprises reacting a compound of the formula h oh I .(ch2)nch-cf2c00h m I i m SiR1R2R3 (22) which comprises reacting a compound of the formula H OH I (CH )nCH-CF2C00H
IE225290A 1989-06-22 1990-06-21 Novel acetylcholinesterase inhibitors IE66155B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP89401775A EP0403713A1 (en) 1989-06-22 1989-06-22 Novel acetylcholinesterase inhibitors

Publications (3)

Publication Number Publication Date
IE902252L true IE902252L (en) 1990-12-22
IE902252A1 IE902252A1 (en) 1991-01-16
IE66155B1 IE66155B1 (en) 1995-12-13

Family

ID=8202963

Family Applications (1)

Application Number Title Priority Date Filing Date
IE225290A IE66155B1 (en) 1989-06-22 1990-06-21 Novel acetylcholinesterase inhibitors

Country Status (19)

Country Link
EP (2) EP0403713A1 (en)
JP (1) JP2879951B2 (en)
KR (1) KR0139529B1 (en)
CN (1) CN1027759C (en)
AR (1) AR247214A1 (en)
AT (1) ATE119535T1 (en)
AU (1) AU626428B2 (en)
CA (1) CA2019231C (en)
DE (1) DE69017543T2 (en)
DK (1) DK0409676T3 (en)
ES (1) ES2072406T3 (en)
FI (1) FI97619C (en)
HU (1) HU210569B (en)
IE (1) IE66155B1 (en)
IL (1) IL94779A (en)
NO (1) NO178374C (en)
NZ (1) NZ234136A (en)
PT (1) PT94449B (en)
ZA (1) ZA904715B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611769A1 (en) * 1993-02-16 1994-08-24 Merrell Dow Pharmaceuticals Inc. Silylated acetylcholinesterase inhibitors
US5523442A (en) * 1993-02-16 1996-06-04 Merrell Pharmaceuticals Inc. Silylated acetylcholinesterase inhibitors
EP0627400A1 (en) * 1993-06-04 1994-12-07 Merrell Dow Pharmaceuticals Inc. Aromatic acetylcholinesterase inhibitors
US5554780A (en) * 1994-05-05 1996-09-10 Merrell Pharmaceuticals Inc. Process for the preparation of 1-(3-trialkylsilylphenyl)-2,2,2-trifluoromethyl ethanone derivatives
US5486638A (en) * 1994-11-08 1996-01-23 Marion Merrell Dow Inc. Process for the preparation of 1-halo-3-trialkysilanyl-benzene derivatives
EP0749972A1 (en) 1995-06-21 1996-12-27 Merrell Pharmaceuticals Inc. A process for preparing 1-(3-trialkylsilylphenyl)-2,2,2-trifluoromethyl ethanone derivatives
US6673784B1 (en) 1996-03-19 2004-01-06 G. D. Searle & Co. Electrophilic ketones for the treatment of herpesvirus infections
CN1059702C (en) * 1997-12-30 2000-12-20 中国科学院上海细胞生物学研究所 Method for cerebral acetylcholinesterase obtained from cells of mamma animals
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6084117A (en) * 1999-11-22 2000-07-04 Albemarle Corporation Production of silated haloarenes by selective silylation of polyhaloarenes
BR112012019923A2 (en) 2010-02-09 2016-08-09 Univ Johns Hopkins methods and compositions for improving cognitive function
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
GEP201706739B (en) 2012-12-13 2017-09-25 H Lundbeck As Compositions comprising vortioxetine and donepezil
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CN107810002B (en) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 Extended release pharmaceutical compositions of levetiracetam

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL25820A (en) * 1966-05-22 1971-02-25 Yissum Res Dev Co Silicon containing beta-hydroxy alpha-phenyl carboxylic acids,their amide and ester derivatives and intermediates for their preparation
US4835099A (en) * 1986-11-20 1989-05-30 Becton, Dickinson And Company Signal enhancement in immunoassay by modulation of enzymatic catalysis

Also Published As

Publication number Publication date
NO902776D0 (en) 1990-06-21
ZA904715B (en) 1991-04-24
NO902776L (en) 1990-12-27
EP0409676B1 (en) 1995-03-08
FI903104A0 (en) 1990-06-20
NZ234136A (en) 1994-04-27
KR0139529B1 (en) 1998-07-01
HU903933D0 (en) 1990-11-28
CA2019231C (en) 2000-07-11
IE66155B1 (en) 1995-12-13
JPH0338591A (en) 1991-02-19
IE902252A1 (en) 1991-01-16
PT94449A (en) 1991-02-08
CN1048389A (en) 1991-01-09
DE69017543D1 (en) 1995-04-13
DE69017543T2 (en) 1995-07-06
FI97619C (en) 1997-01-27
KR910000757A (en) 1991-01-30
HUT54695A (en) 1991-03-28
PT94449B (en) 1997-02-28
ATE119535T1 (en) 1995-03-15
AU5758490A (en) 1991-01-03
CA2019231A1 (en) 1990-12-22
CN1027759C (en) 1995-03-01
NO178374B (en) 1995-12-04
DK0409676T3 (en) 1995-03-27
AU626428B2 (en) 1992-07-30
EP0403713A1 (en) 1990-12-27
EP0409676A1 (en) 1991-01-23
ES2072406T3 (en) 1995-07-16
AR247214A1 (en) 1994-11-30
HU210569B (en) 1995-05-29
JP2879951B2 (en) 1999-04-05
FI97619B (en) 1996-10-15
IL94779A (en) 1996-09-12
NO178374C (en) 1996-03-13

Similar Documents

Publication Publication Date Title
IE902252L (en) Novel acetylcholinesterase inhibitors
Molander et al. Organoyttrium-catalyzed sequential cyclization/silylation reactions of 1, 5-dienes and 1, 6-dienes
Danheiser et al. Scope and stereochemical course of the addition of (trimethylsilyl) allenes to ketones and aldehydes. A regiocontrolled synthesis of homopropargylic alcohols
Jarvie et al. Preparation and Characterization of Octaphenylcyclotetrasilane
Wovkulich et al. Stereoselective total synthesis of 1α, 25S, 26-trihydroxycholecalciferol
KR100336547B1 (en) Silylated acetylcholinesterase inhibitors
CA2164303C (en) Aromatic acetylcholinesterase inhibitors
US5693668A (en) Acetylcholinesterase inhibitors
Valenti et al. Convenient synthesis of silylketenes from 1-tert-butoxy-2-silylethynes
Padwa et al. Studies dealing with the aza Claisen rearrangement of 2-allyloxy-substituted oxazoles
FR2575466A1 (en) NOVEL SILICON HEXACOORDIN COMPLEXES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION
Kato et al. Specific generation of lithiated 3-trimethylsiloxy-1, 2-propadiene derivatives from 1-(trimethylsilyl) propargyl alcohols.
AU611683B2 (en) Novel substituted silyl alkylene amines
Chen et al. Prostaglandins and congeners. 27. Synthesis of biologically active 16-halomethyl derivatives of 15-deoxy-16-hydroxyprostaglandin E2
US5523442A (en) Silylated acetylcholinesterase inhibitors
HU215133B (en) Process for the preparation of 1-(3-trialkylsilylphenyl)-2,2,2-trifluoromethyl ethanone derivatives
US5216017A (en) Pyrrolo[2,3-b]indole-ketones and analogs
JPH07278155A (en) Aminoboric acid derivative, its production, and its use as synthetic intermediate
US3529005A (en) Silicon-containing steroids
EP0493209A1 (en) Fluoroketone derivatives of silylated pyridines
US3637782A (en) 1-silanaphthalenes
Rosenberg et al. The synthesis of 2-silanorcaranes
EP0193450A2 (en) Process for the preparation of diphenylazomethines
Stoyanovich et al. Stable isomeric benzonitrile oxides derived from 6-chloro-2, 4-dimethoxyaniline
Inoue et al. Anionic rearrangement of the germyl and silyl groups in [2-(trimethylgermyl)-2-(trimethylsilyl) ethyl] dimethylammonium N-methylide and related compounds

Legal Events

Date Code Title Description
MM4A Patent lapsed